Leaders with Boehringer Ingelheim Pharmaceuticals Inc. and the Duke Clinical Research Institute (DCRI) recently expanded the current Idiopathic Pulmonary Fibrosis – Prospective Outcomes (IPF-PRO) Registry.
This registry is the biggest patient registry that has been created to disclose IPF insights. IPF is a rare, serious disease based in the lungs.
"Expanding the IPF-PRO Registry is important to the IPF community because it will substantially advance the understanding of this rare and fatal lung disease," Dr. Scott Palmer, director of pulmonary research at DCRI, said. "In collecting data from a larger, more diverse group of patients from multiple centers nationwide -- all of whom are newly diagnosed with IPF -- this registry will allow us to better assess the impact of the disease over time on clinical and patient centered outcomes."
With the expansion, the study enrollment for IPF should rise from 300 patients based at 18 study sites to an estimated 1,500 patients at 45 study sites.
"The IPF-PRO Registry, which represents a valuable academic-industry partnership, is a substantial and important opportunity for Boehringer Ingelheim to contribute to the advancement of our understanding of IPF -- independent of any particular medication or drug discovery effort," Dr. Craig Conoscenti, principal expert of clinical development and medical affairs at Boehringer Ingelheim Pharmaceuticals, said. "We are proud to continue our collaborative partnership with the Duke Clinical Research Institute, as we bring our unique strengths and expertise together in working toward improving the lives of those living with IPF."
